MedTrace Logo

Efficacy of Erenumab on Functional Impact of Migraine

NCT04465357 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2022-10-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the efficacy of erenumab on functional impact due to Migraine in adults.

Conditions

Interventions

DRUG

Erenumab-Aooe 140 MG/ML [Aimovig]

140 mg/mL administered subcutaneously

Sponsors & Collaborators

  • Clinvest Research, LLC

    collaborator INDUSTRY

  • Smith, Timothy R., M.D.

    collaborator INDIV

  • Merle Diamond

    lead OTHER

Principal Investigators

  • Merle Diamond, MD · Diamond Headache Clinic

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-22
Primary Completion
2022-06-03
Completion
2022-06-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04465357 on ClinicalTrials.gov